Cargando…

Pathogenesis from Inflammation to Cancer in NASH-Derived HCC

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and one of the deadliest cancers worldwide. As opposed to the majority of patients with HCC, approximately 20–30% of cases of non-alcoholic steatohepatitis (NASH)-derived HCC develop malignant tumours in the absence of li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Simiao, Wang, Jingxiao, Zheng, Haocheng, Wang, Ruilin, Johnson, Nadia, Li, Tao, Li, Ping, Lin, Jie, Li, Yuan, Yan, Jin, Zhang, Ying, Zhu, Zhenyu, Ding, Xia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426868/ https://www.ncbi.nlm.nih.gov/pubmed/36051860 http://dx.doi.org/10.2147/JHC.S377768

Ejemplares similares

The Pathogenesis of HCC Driven by NASH and the Preventive and Therapeutic Effects of Natural Products
por: Shao, Gaoxuan, et al.
Publicado: (2022)

The paradox of immunotherapy in NASH-HCC
por: Peng, Yao, et al.
Publicado: (2021)

Lipid Related Genes Altered in NASH Connect Inflammation in Liver Pathogenesis Progression to HCC: A Canonical Pathway
por: Desterke, Christophe, et al.
Publicado: (2019)

Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC
por: Boslem, Ebru, et al.
Publicado: (2023)

Recent updates on the role of the gut-liver axis in the pathogenesis of NAFLD/NASH, HCC, and beyond
por: Ohtani, Naoko, et al.
Publicado: (2023)

Mitochondrial Dysfunction in the Transition from NASH to HCC
por: Léveillé, Mélissa, et al.
Publicado: (2019)

Evolving Concepts in the Pathogenesis of NASH: Beyond Steatosis and Inflammation
por: Peverill, William, et al.
Publicado: (2014)

CXCR2 inhibition enables NASH-HCC immunotherapy
por: Leslie, Jack, et al.
Publicado: (2022)

Erratum for the Research Article: “Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC”
Publicado: (2023)

Molecular Pathogenesis of NASH
por: Caligiuri, Alessandra, et al.
Publicado: (2016)

NASH limits anti-tumour surveillance in immunotherapy-treated HCC
por: Pfister, Dominik, et al.
Publicado: (2021)

Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC
por: Dongiovanni, Paola, et al.
Publicado: (2021)

Prohibitin-induced, obesity-associated insulin resistance and accompanying low-grade inflammation causes NASH and HCC
por: Ande, Sudharsana R., et al.
Publicado: (2016)

Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC
por: Longo, Miriam, et al.
Publicado: (2021)

Hepatocyte phosphatase DUSP22 mitigates NASH-HCC progression by targeting FAK
por: Ge, Chenxu, et al.
Publicado: (2022)

Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies
por: Pal Chaudhary, Surendra, et al.
Publicado: (2023)

Suppression of NASH-Related HCC by Farnesyltransferase Inhibitor through Inhibition of Inflammation and Hypoxia-Inducible Factor-1α Expression
por: Yamada, Kohei, et al.
Publicado: (2023)

HCC Development Is Associated to Peripheral Insulin Resistance in a Mouse Model of NASH
por: De Minicis, Samuele, et al.
Publicado: (2014)

Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC
por: Grohmann, Marcus, et al.
Publicado: (2018)

Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC
por: Sydor, Svenja, et al.
Publicado: (2020)

The Role of Oxidative Stress in NAFLD–NASH–HCC Transition—Focus on NADPH Oxidases
por: Gabbia, Daniela, et al.
Publicado: (2021)

Unraveling the molecular links between benzopyrene exposure, NASH, and HCC: an integrated bioinformatics and experimental study
por: Yang, Zheming, et al.
Publicado: (2023)

FGF9 Recruits β‐Catenin to Increase Hepatic ECM Synthesis and Promote NASH‐Driven HCC
por: Zhang, Lei, et al.
Publicado: (2023)

HIF2α Activation in NASH: A New Force Pushing Toward HCC
por: Clavería-Cabello, Alex, et al.
Publicado: (2021)

A maternal high-fat diet induces fetal origins of NASH-HCC in mice
por: Takiyama, Takao, et al.
Publicado: (2022)

Metformin Actions on the Liver: Protection Mechanisms Emerging in Hepatocytes and Immune Cells against NASH-Related HCC
por: Zhang, Yueqi, et al.
Publicado: (2021)

Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
por: Kim, Hyunmi, et al.
Publicado: (2021)

Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies
por: Gutiérrez-Cuevas, Jorge, et al.
Publicado: (2022)

Unraveling the Transcriptional Dynamics of NASH Pathogenesis Affecting Atherosclerosis
por: van den Hoek, Anita M., et al.
Publicado: (2022)

Editorial: Immune mechanisms of inflammation in NASH
por: Hirsova, Petra, et al.
Publicado: (2022)

Elucidating Cuproptosis-Associated Genes in the Progression from Nash to HCC Using Bulk and Single-Cell RNA Sequencing Analyses and Experimental Validation
por: Zhao, Zizuo, et al.
Publicado: (2023)

Lack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling
por: Zheng, Qianqian, et al.
Publicado: (2020)

Dietary fat/cholesterol-sensitive PKCβ-RB signaling: Potential role in NASH/HCC axis
por: Huang, Wei, et al.
Publicado: (2017)

Dietary and Genetic Cholesterol Loading Rather Than Steatosis Promotes Liver Tumorigenesis and NASH-Driven HCC
por: Ribas, Vicent, et al.
Publicado: (2021)

Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma
por: Kutlu, Ozlem, et al.
Publicado: (2018)

From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors, and Prevention
por: Motta, Benedetta Maria, et al.
Publicado: (2023)

Current and Potential Therapies Targeting Inflammation in NASH
por: Albhaisi, Somaya, et al.
Publicado: (2021)

HCC Heterogeneity: Molecular Pathogenesis and Clinical Implications
por: Fransvea, Emilia, et al.
Publicado: (2009)

Hyperlipidemia May Synergize with Hypomethylation in Establishing Trained Immunity and Promoting Inflammation in NASH and NAFLD
por: Drummer, Charles I. V., et al.
Publicado: (2021)

Identification of ferroptosis-related genes in the progress of NASH
por: He, Linwei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bn60ic0npt6ihphsja94dp5b4b